Leukemia, Myeloid 
Welcome,         Profile    Billing    Logout  

15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukemia, Myeloid
NOPHO-DBH, NCT01828489 / 2012-002934-35: Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years

Recruiting
3
300
Europe, RoW
Randomisation course 1 mitoxantrone versus DaunoXome, Randomisation course 2 ADxE versus FLADx
Vastra Gotaland Region
Pediatric Acute Myeloblastic Leukemia
03/18
03/23
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Checkmark In 2nd line CML chronic phase pts
Feb 2014 - Feb 2014: In 2nd line CML chronic phase pts
Active, not recruiting
3
90
Japan, US, Europe, RoW
Nilotinib, Imatinib
Novartis Pharmaceuticals
Myelogenous Leukemia, Chronic
10/18
10/18
NCT01041703: Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Recruiting
3
747
US, RoW
clofarabine, cytarabine, daunorubicin hydrochloride, decitabine
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Leukemia
02/19
 
NCT00466115: A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies

Not yet recruiting
2
18
US
MS-275, GM-CSF
Johns Hopkins University
Myelodysplastic Syndrome, Acute Myeloid Leukemia
 
04/07
NCT00066300: Allogeneic Peripheral Stem Cell Transplantation Followed By Donor Lymphocyte Infusions in Treating Patients With Hematologic Cancer

Active, not recruiting
2
US
graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
 
 
NCT01413880: Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly (AML)

Active, not recruiting
2
165
US
FLAM, alvocidib, arC, novanrone, 7&3, ara-c, daunorubicin or idarubicin
Sidney Kimmel Comprehensive Cancer Center
Acute Myelogenous Leukemia
07/13
12/15
NCT02188706: A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
120
US
Decitabine, Dacogen, Carboplatin, Paraplatin, Arsenic Trioxide, ATO, Trisenox
M.D. Anderson Cancer Center, TEVA, Leukemia SPORE
Leukemia
07/26
07/26
NCT00005846: Tipifarnib in Treating Patients With Myeloproliferative Disorders

Active, not recruiting
1/2
US
tipifarnib
Stanford University, National Cancer Institute (NCI)
Leukemia, Myelodysplastic/Myeloproliferative Neoplasms
 
 
NCT01756677: Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients

Checkmark Efficacy and safety data from P1 portion of P1/2 trial in AML
Jun 2016 - Jun 2016: Efficacy and safety data from P1 portion of P1/2 trial in AML
Checkmark asco-2015
May 2015 - May 2015: asco-2015
Active, not recruiting
1/2
24
US
Cytarabine, Cytosar, Ara-C, DepoCyt, Cytosine arabinosine hydrochloride, Low dose Ara-C, LDAC, Lintuzumab-Ac225, Lintuzumab, Lasix, furosemide, Spironolactone
M.D. Anderson Cancer Center, Actinium Pharmaceuticals
Leukemia
10/16
 
NCT00960050: Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Active, not recruiting
1
173
US
polymorphism analysis, laboratory biomarker analysis, medical chart review, assessment of therapy complications
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Leukemia, Lymphoma, Methemoglobinemia, Nonmalignant Neoplasm
05/15
 
NCT00302016 / 2005-001818-41: Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

No Longer Available
N/A
US, Canada, Europe, RoW
AMN107
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
11/08
 
NCT00854841: The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Available
N/A
RoW
Dasatinib and Imatinib, Sprycel and Gliveec
Pusan National University Hospital
Chronic Myeloid Leukemia
 
 
NCT00413270: Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

No Longer Available
N/A
Canada
nilotinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
 
 
NCT01549548: Compassionate Use Ponatinib

No Longer Available
N/A
US
Ponatinib, AP24534
OHSU Knight Cancer Institute, Ariad Pharmaceuticals
Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia
 
 
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No Longer Available
N/A
US
Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
01/15
01/15

Download Options